Loading organizations...
§ Private Profile · London, UK
OSSTEC is a technology company.
OSSTEC develops advanced orthopaedic implants, specifically partial knee replacements, leveraging metal 3D printing technology. Their core product is engineered to emulate the porous structure of natural bone, aiming to facilitate superior integration and accelerate bone healing. This innovative additive manufacturing approach delivers regenerative orthopedic solutions for surgical applications.
The company was founded in 2021 by Maxwell Munford, originating from his PhD research project at Imperial College London. Munford's foundational insight stemmed from exploring the transformative potential of 3D printing for surgical applications, which directly led to the development of these advanced bone healing implants. His academic pedigree underpins the venture's technical sophistication.
OSSTEC's products target patients undergoing partial knee replacement surgeries, offering an alternative designed for enhanced biological integration. The company's vision centers on improving long-term patient outcomes in orthopedics by advancing additive manufacturing and regenerative medicine, providing implant technologies that promote natural bone regeneration and more effective recovery.
OSSTEC has raised $7.4M across 3 funding rounds.
OSSTEC has raised $7.4M in total across 3 funding rounds.
OSSTEC has raised $7.4M across 3 funding rounds. Most recently, it raised $3.4M Other Equity in April 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 8, 2025 | $3.4M Venture Round | Empirical Ventures | — | Announced |
| Mar 1, 2025 | $3M Seed | — | Elbow Beach Capital | Announced |
| Mar 1, 2023 | $1M Seed | Oxford Innovation Finance | Elbow Beach Capital | Announced |
OSSTEC has raised $7.4M in total across 3 funding rounds.
OSSTEC's investors include Empirical Ventures, Elbow Beach Capital, Oxford Innovation Finance.
OSSTEC is a medtech startup developing innovative 3D-printed partial knee implants that combine biomimetic cementless fixation with lattice structures mimicking bone's trabecular properties, aimed at improving patient outcomes in osteoarthritis treatment.[1][2][3] These implants target patients needing knee replacements, addressing issues like bone loss and complications from traditional designs by promoting natural bone ingrowth, enabling outpatient care, and enhancing long-term fixation for active lifestyles.[1][2][4] Serving orthopedic surgeons and patients globally—with a US market launch focus—the company solves key problems in orthopedics, such as revision surgeries and suboptimal implant performance, backed by strong growth including a £2.5M funding round closed in early 2025 to fund regulatory approval, team expansion to nine members, and first revenues.[1][4][5]
OSSTEC was founded in May 2021 by Dr. Maxwell Munford, stemming from his PhD project at Imperial College London's Department of Mechanical Engineering, which explored 3D printing applications in surgery.[2][4] Munford, influenced by a business-oriented upbringing, gained formalized startup training through the MedTech SuperConnector program, propelling the idea forward; he later became an Enterprise Fellow at the Royal Academy of Engineering.[2] Early traction included £800,000 in public funding, preclinical studies in sheep and human cadavers, an oversubscribed £2M (later reported as £1.2M seed plus additional) round in 2023-2024, team growth to eight members, product unveiling, and key events like cadaver labs at HSS New York and conferences (ISTA, AAHKS, AAOS).[1][2][4] Led by surgeons like Chief Medical Officer Alex Liddle and engineers, the company evolved from research to commercialization, supported by Imperial's networks including a San Francisco Venture Trek.[4]
OSSTEC rides the wave of advanced manufacturing in medtech, particularly 3D printing for personalized orthopedics, amid rising global knee replacement demand (1.3M annually) driven by aging populations and osteoarthritis prevalence.[2] Timing aligns with regulatory shifts favoring innovative implants and DeepTech investment surges, as seen in their funding from Imperial-linked VCs and US networking.[4][5] Market forces like high revision rates from bone quality loss favor their bone-mimicking tech, potentially disrupting a field dominated by legacy designs while influencing ecosystems through Imperial spinouts, surgeon adoption, and outpatient trends that cut costs and improve access.[1][2][4]
OSSTEC is poised for US regulatory approval, initial UK surgeries, and first revenues in 2025, scaling via its expanded team and investor backing.[1][4] Trends like AI-optimized 3D printing, value-based care emphasizing durability, and global ortho demand will propel growth, potentially expanding to full knee or other joints. Their surgeon-led model could redefine implant standards, amplifying influence in medtech innovation hubs like Imperial and US markets—empowering more active lives, one step further.[1][2]